SVF Vaccines develops therapeutic vaccines and immunotherapies for the treatment of serious infectious diseases. The lead programme SVF-001 targets chronic hepatitis B and D and is designed to activate both neutralising antibodies and T cells.

The company is preparing SVF-001 for clinical development. In 2026, a collaboration with Touchlight was established around cell-free DNA manufacturing to support the path towards Phase 1. The platform has previously been clinically validated through a Phase 1 study of the company’s universal coronavirus vaccine SVF-002.

In brief:

• Phase 1 for SVF-001 is planned for 2027
• Focus on hepatitis B and D
• The platform has already been validated in clinical Phase 1 through SVF-002